Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Head-to-head evidence comparison — which supplement is right for you?
Probiotics wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Probably helps
18 of 26 studies with measurable effects showed benefit.
Top outcomes
Verdict
Likely helps
13 of 15 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (2)
Outcomes where both Probiotics and Saccharomyces Boulardii have evidence — compare verdict strength side-by-side.
10-20 billion CFU
With or without food (strain-dependent), Same time daily for consistency
Capsules with multiple strains
250-500mg (5-10 billion CFU) daily
With or without food, At least 2 hours away from antifungals
Capsules (lyophilized)
2-4 weeks
4-8 weeks
4-8 weeks
First 1-2 weeks
During use
1-3 days
1-2 weeks
Preventive Effect of Probiotics on Oral Mucositis Induced by Cancer Treatment: A Systematic Review and Meta-Analysis
International journal of molecular sciences (2022) · Meta analysis · n=708
Three trials using Lactobacilli-based probiotics reported that the incidence of oral mucositis in the probiotic group was significantly low (risk ratio [RR] = 0.84, 95% confidence interval [CI] = 0.77−0.93, p = 0.0004).
Probiotics for treating acute infectious diarrhoea
The Cochrane database of systematic reviews (2020) · Meta analysis · n=12127
Effect size was similar in the sensitivity analysis and marked heterogeneity persisted.
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children
The Cochrane database of systematic reviews (2017) · Meta analysis · n=9955
A complete case analysis (i.e. participants who completed the study) among trials investigating CDAD (31 trials, 8672 participants) suggests that probiotics reduce the risk of CDAD by 60%.
Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication of Helicobacter pylori: a meta-analysis
Frontiers in cellular and infection microbiology (2025) · Meta analysis · n=5036
S. boulardii supplementation in traditional eradication therapy significantly improves the H. pylori eradication rate and reduces the total adverse effects and incidence of diarrhea, bloating, constipation, and nausea.
Probiotics for treating acute infectious diarrhoea
The Cochrane database of systematic reviews (2020) · Meta analysis · n=12127
Effect size was similar in the sensitivity analysis and marked heterogeneity persisted.
The use of probiotics and prebiotics in decolonizing pathogenic bacteria from the gut; a systematic review and meta-analysis of clinical outcomes
Gut microbes (2024) · Meta analysis · n=2871
This review aims to analyze available evidence from human-controlled trials to determine the effect size of probiotic interventions in decolonizing AMR pathogenic bacteria from the gut.
Based on meta-analyses showing benefits for IBS and digestive symptoms. Effect sizes varied considerably between studies with low to very low certainty of evidence. Initial GI symptoms common when starting but typically resolve within 1-2 weeks.
Based on multiple meta-analyses showing 1.1-1.6 day reduction in diarrhea duration. Effect size appears to plateau at standard therapeutic doses. Limited data on doses above 20 billion CFU.
AI-estimated from published studies. Interpret as directional guidance.
Probiotics has a higher evidence score (9/10 vs 9/10) and wins in 1 of 3 categories.
For reduce inflammation, Probiotics has a higher relevance score (95 vs 90).
No known interactions between Probiotics and Saccharomyces Boulardii have been documented in our database. However, always consult a healthcare provider before combining supplements.